Abstract

21
Several animal models exist to evaluate the immunogenicity and protective efficacy of that induces an attack rate of 75% in the Aotus. After primary challenge, the dose required to 31 induce an attack rate of 75% was calculated to be 1 x 10 11 cfu. Shigella-specific Immune 32 responses were low after primary challenge and subsequently boosted upon re-challenge. 33 However, pre-existing immunity derived from the primary challenge was insufficient to protect 34 against the homologous Shigella serotype. susceptible are children in day-care centers, migrant workers, travelers to developing countries, 50 and homosexual men (3-6). The low infectious dose, the fecal-oral route of transmission, and 51 the emergence of resistance to multiple antibiotics among Shigella isolates pose a major public 52 health problem throughout the developing world and necessitate the development of a safe, 53 efficacious vaccine. 54 There are several animal models to investigate pathogenic mechanisms utilized by 55 Shigella spp. and to evaluate the immunogenicity and protective efficacy of candidate vaccines. 56 The two most widely used models for vaccine development include a murine pulmonary 57 challenge model (7), which is useful for preliminary screening of vaccine candidates, and a 58 guinea pig keratoconjunctivitis model (8). The ability of Shigella to invade the corneal 59 epithelium of guinea pigs and spread to contiguous cells causing keratoconjunctivitis, provides a 60 model system that mimics the invasive process which occurs in the mucosal epithelium. acceptance of significance set to the p<0.05 level.
RESULTS
193
Dose finding and re-challenge study: Clinical symptoms, microbiology and challenge results.
194
Results from a preliminary, pilot study indicated that oral challenge with 5 x 10 9 cfu of S. 
213
Tissues from the peritoneum tested negative for enteropathogens.
214
The clinical symptoms incidence, which captures disease and death due to the infection, 215 was used to calculate a dose of 1 x 10 11 cfu to result in a 75% attack rate. The dose of S. flexneri The animals were rested for 9 weeks and then all groups were orally challenged with 1 x 221 10 11 cfu of S. flexneri 2a, 2457T. Veterans from the primary challenge were used to determine 222 if protection could be achieved after homologous re-challenge whereas the veteran PBS control 223 group was used to confirm that the calculated dose would result in a ≥ 75% attack rate.
224
Challenge of the veteran PBS groups with S. flexneri 2a, 2457T resulted in an 80% attack 225 rate confirming previous results (Table 1) . Animals previously infected with S. flexneri 2a,
226
2457T were not protected upon subsequent re-challenge with a homologous strain ( determined by ELISA (Figure 1 ). Shigella-specific antibodies were not detected in serum of 242 animals treated with PBS at any time point during the primary challenge phase of the study.
243
Furthermore, baseline Shigella-specific antibodies were low across all groups prior to challenge.
244
The serum IgG titers directed to LPS, Invaplex, IpaB and IpaC followed a dose-dependent cfu were low, with less than 25% of animals seroconverting to any of the antigens (Figure 1 ).
260
Moderate levels of Shigella-specific IgA were elicited after oral inoculation with 5 x 10 11 cfu of S. and colonization rates were also substantial (75-100%) . between the two Aotus studies due in part to the small number of animals in each study.
356
Future work using more animals should help to address the inconsistency.
357
The majority of results achieved in the current study are consistent with reports describing oral suggesting the monkey models may mimic, in part, the immunogenicity and reactogenicity in 439 humans.
440
The described Aotus nancymaae model provides another means to study pathogenesis * One animal excluded from data analysis due to diarrhea for two days prior to challenge ** One animal removed from study on day 6 post-challenge; full duration data not collected *** One animal removed from study at 2 days psot-challenge; excluded from diarrhea incidence data analysis 
